+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating two methods of planning spine stabilization surgeries for patients with traumatic injuries to the lower thoracic or lumbar spine. The study compares conventional preoperative planning using CT scans with planning based on patient-specific 3D-printed spine models. This trial intends to assess how these approaches affect surgical outcomes such as blood loss during surgery. Participants undergo standard bisegmental posterior spine stabilization surgery through a midline approach. One group receives surgery planned with conventional CT scans and fluoroscopy guidance, while the other group has surgery planned with the aid of 3D-printed spine models along with the same fluoroscopy guidance. Both groups undergo the same surgical technique with different preoperative planning tools. During the study, researchers will monitor surgery-related factors including blood loss during the operation, surgical duration, accuracy of pedicle screw placement, and the length of the surgical incision. Assessments occur during surgery and postoperatively, with screw placement accuracy evaluated on the first day after surgery and incision length checked around the time of suture removal approximately 10 to 14 days post-surgery. The study is randomized and single-blinded, involving follow-up to measure these outcomes.

All AgesAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
E

Actively Recruiting

Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
201 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
S

Actively Recruiting

Researchers are evaluating the use of BIOTRONIK dual-chamber pacemakers that combine left bundle branch area pacing LBBAP with Closed Loop Stimulation CLS in patients who have sinus node dysfunction SND and atrioventricular AV conduction disorders. This observational study aims to understand how this combined pacing method works in everyday clinical practice and whether it can help reduce atrial fibrillation detected by the device over 24 months. The goal is to gather real-world evidence to optimize pacemaker programming and improve patient outcomes. Participants receive permanent dual-chamber pacemakers with a ventricular lead placed in the left bundle branch area, activating the CLS rate-responsive algorithm. The study focuses on patients implanted with these devices who have no prior history of atrial fibrillation. The study follows about 150 patients for 24 months after implantation, collecting data on device-detected atrial fibrillation episodes, heart rate patterns, and pacing behavior. This is a prospective observational submodule of the BIOSTREAM.CSP registry without a control group. During the study, researchers monitor device-recorded atrial fibrillation incidence and burden from CLS activation up to 24 months. They also analyze heart rate histograms at one and two years after implantation. Patients are enrolled in the BIOSTREAM.CSP registry and are followed through routine clinical care with data collected on pacing rates and arrhythmia episodes. The study aims to provide insights into the clinical performance of CLS combined with LBBAP to inform decisions on pacemaker programming and reduce atrial arrhythmias.

Age: 18Years - 18YearsAll Genders
12 locations
R

Actively Recruiting

This trial evaluates primary coxarthrosis patients receiving cementless total hip arthroplasty THA. It compares modular dual mobility inserts with ceramic multilayer coating against standard polyethylene inserts with metal heads. The study aims to assess if cobalt and chromium serum metal ion levels with the dual mobility system are similar to those with standard metal-on-polyethylene implants, as metal ion release is a concern and previous studies lacked a proper control group. Participants will be randomly assigned to receive either the Dual Mobility Cup device or the Standard Acetabular component device that includes polyethylene with vitamin E inlay and a metal head. Both interventions are established options in THA for conditions like coxarthrosis, rheumatic arthritis, hip fractures, and femoral head necrosis. The trial involves the use of cementless acetabular cups and will follow patients over several years. During the study, participants will undergo blood tests to measure serum cobalt and chromium levels at 12 months post-surgery. Functional outcomes will be assessed using the Harris Hip Score at 3 months, 12 months, and 3 years after surgery. Gait analysis and patient satisfaction evaluations will be performed before surgery and during follow-up visits. Radiologic assessments of cup positioning, radiolucencies, and heterotopic ossification will be done immediately post-op and at multiple intervals up to 3 years. Participants will be monitored for adherence and safety throughout the study duration, which extends to at least 3 years after surgery.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the software Lipidica 1.0, designed to process lipidomic data from an in-house diagnostic device, for screening pancreatic cancer PaC in people at high risk due to family history, gene mutations, or hereditary pancreatic diseases. Pancreatic cancer often has a poor prognosis due to late detection and rapid progression. Early screening in high-risk groups may improve outcomes, and this study builds on previous findings showing distinct lipid profiles in pancreatic cancer patients. Participants are divided into two groups those with confirmed resectable pancreatic cancer, who will have one baseline visit for blood sampling to analyze lipid profiles and tumor markers and those at high risk without cancer, who will have two or three visits over up to 12 months. The high-risk group undergoes blood tests and medical imaging such as endoscopic ultrasonography, magnetic resonance, or computed tomography. The softwares ability to distinguish between cancer patients and high-risk individuals without cancer is the main focus. Participants will attend visits for blood collection and imaging at the start and end of the study, with some having an additional visit based on initial results. Blood tests include lipidomic analysis, tumor markers CA 19-9 and CEA, HbA1c, and hCG for women of childbearing potential. Imaging assessments occur up to three times per participant. Researchers will analyze these data to verify the softwares performance in differentiating disease presence. The study is expected to continue for about three years, with interim analysis after one year.

Age: 18Years +All GendersPhase Not Applicable
16 locations
E

Actively Recruiting

Researchers are evaluating methods to reduce pain during venipuncture in children aged 3 to 15 years. This randomized controlled trial compares virtual reality distraction, topical anesthetic cream EMLA, and standard care to find out if virtual reality can reduce pain more effectively than EMLA cream or no additional intervention. The study plans to include 450 children, assessing pain immediately after venipuncture using the Wong-Baker Faces Pain Rating Scale. Children in the virtual reality group wear a Meta Quest 3 headset that shows the same 360 wildlife video during the blood draw, allowing head movement to change the view direction. The EMLA cream group receives topical lidocaine-prilocaine cream applied to the venipuncture site with an occlusive dressing left for at least 60 minutes before the procedure. The standard care group receives routine nursing care without additional pain-reducing interventions. Participants will be involved during the venipuncture procedure with pain measured right after the procedure. The study collects data on pain intensity to compare the effectiveness of the three approaches. Participants are monitored during the venipuncture visit, and the trial runs until June 2027 with all procedures and assessments focused on this single visit and immediate pain measurement.

Age: 3Years - 15YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating whether adding duroplasty, a surgical procedure that expands the tough membrane around the spinal cord, improves outcomes after severe cervical spinal cord injury. This trial focuses on adults with acute, severe injuries in the neck area who require surgery within 72 hours. The study aims to determine if duroplasty combined with standard bony decompression surgery enhances muscle strength and functional recovery compared to bony decompression alone. Participants will be randomly assigned to receive either standard spinal surgery including laminectomy alone or the same surgery plus duroplasty. Some patients may also join an optional mechanistic sub-study where probes and microdialysis catheters monitor spinal cord pressure, blood flow, metabolism, and inflammation at the injury site. The study will recruit around 222 to 260 patients over four years, including sites in the UK and internationally. During the study, participants will be assessed at baseline, 3, 6, and 12 months after surgery using questionnaires and physical examinations to measure muscle strength, hand function, walking ability, bladder and bowel control, and quality of life. Some will have MRI scans at 2 weeks and 6 months, and safety outcomes such as complications, additional surgeries, and mortality will be tracked up to 12 months. Follow-up lasts one year to evaluate recovery and treatment impact.

Age: 16Years +All GendersPhase Not Applicable
34 locations

1-10 of 22

1